Aperio Group LLC Boosts Stake in Mallinckrodt PLC (MNK)  Alanna Baker | Aug 17th, 2018
Aperio Group LLC lifted its position in Mallinckrodt PLC (NYSE:MNK) by 128.1% during the second quarter, HoldingsChannel reports. The institutional investor owned 196,129 shares of the company's stock after buying an additional 110,146 shares during the quarter. Aperio Group LLC's holdings in Mallinckrodt were worth $3,660,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Victory Capital Management Inc. bought a new stake in shares of Mallinckrodt in the 1st quarter worth $104,000. Bronfman E.L. Rothschild L.P. raised its stake in shares of Mallinckrodt by 11,188.0% in the 1st quarter. Bronfman E.L. Rothschild L.P. now owns 10,385 shares of the company's stock worth $150,000 after buying an additional 10,293 shares in the last quarter. Virginia Retirement Systems ET AL bought a new stake in shares of Mallinckrodt in the 1st quarter worth $175,000. Financial Gravity Wealth Inc. bought a new stake in shares of Mallinckrodt in the 1st quarter worth $182,000. Finally, TLP Group LLC bought a new stake in shares of Mallinckrodt in the 1st quarter worth $208,000. Get Mallinckrodt alerts:
Shares of MNK stock opened at $34.14 on Friday. Mallinckrodt PLC has a 1-year low of $11.65 and a 1-year high of $41.70. The company has a current ratio of 2.27, a quick ratio of 2.06 and a debt-to-equity ratio of 0.98. The firm has a market cap of $2.59 billion, a PE ratio of 4.56, a price-to-earnings-growth ratio of 0.48 and a beta of 1.36.
Mallinckrodt (NYSE:MNK) last issued its quarterly earnings results on Tuesday, August 7th. The company reported $1.78 earnings per share for the quarter, beating analysts' consensus estimates of $1.48 by $0.30. Mallinckrodt had a return on equity of 10.39% and a net margin of 59.85%. The business had revenue of $631.70 million for the quarter, compared to the consensus estimate of $621.15 million. equities research analysts anticipate that Mallinckrodt PLC will post 6.67 EPS for the current year.
A number of brokerages recently issued reports on MNK. Leerink Swann lifted their target price on Mallinckrodt from $12.00 to $27.00 and gave the stock a "market perform" rating in a report on Wednesday, August 8th. Morgan Stanley decreased their target price on Mallinckrodt from $27.00 to $14.00 and set an "equal weight" rating on the stock in a report on Wednesday, May 9th. SunTrust Banks lifted their target price on Mallinckrodt to $32.00 and gave the stock a "positive" rating in a report on Monday. They noted that the move was a valuation call. Mizuho restated a "hold" rating and issued a $15.00 target price on shares of Mallinckrodt in a report on Thursday, May 3rd. Finally, Canaccord Genuity lifted their target price on Mallinckrodt from $14.00 to $22.00 and gave the stock a "hold" rating in a report on Thursday, July 19th. Three analysts have rated the stock with a sell rating, fourteen have issued a hold rating and five have assigned a buy rating to the company's stock. The stock currently has an average rating of "Hold" and a consensus price target of $31.53.
Mallinckrodt Profile
Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.
Featured Story: Marijuana Stocks Investing Considerations
Want to see what other hedge funds are holding MNK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mallinckrodt PLC (NYSE:MNK). Mallinckrodt Mallinckrod